| Autor: |
Barghorn, Stefan, Nimmrich, Volker, Striebinger, Andreas, Krantz, Carsten, Keller, Patrick, Janson, Bodo, Bahr, Michael, Schmidt, Martin, Bitner, Robert S., Harlan, John, Barlow, Eve, Ebert, Ulrich, Hillen, Heinz |
| Předmět: |
|
| Zdroj: |
Journal of Neurochemistry; Nov2005, Vol. 95 Issue 3, p834-847, 14p |
| Abstrakt: |
Amyloid β-peptide (Aβ)1−42 oligomers have recently been discussed as intermediate toxic species in Alzheimer's disease (AD) pathology. Here we describe a new and highly stable Aβ1−42 oligomer species which can easily be prepared in vitro and is present in the brains of patients with AD and Aβ1−42-overproducing transgenic mice. Physicochemical characterization reveals a pure, highly water-soluble globular 60-kDa oligomer which we named ‘Aβ1−42 globulomer’. Our data indicate that Aβ1−42 globulomer is a persistent structural entity formed independently of the fibrillar aggregation pathway. It is a potent antigen in mice and rabbits eliciting generation of Aβ1−42 globulomer-specific antibodies that do not cross-react with amyloid precursor protein, Aβ1−40 and Aβ1−42 monomers and Aβ fibrils. Aβ1−42 globulomer binds specifically to dendritic processes of neurons but not glia in hippocampal cell cultures and completely blocks long-term potentiation in rat hippocampal slices. Our data suggest that Aβ1−42 globulomer represents a basic pathogenic structural principle also present to a minor extent in previously described oligomer preparations and that its formation is an early pathological event in AD. Selective neutralization of the Aβ globulomer structure epitope is expected to have a high potential for treatment of AD. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text